Given the limited access to clinical material for studying the pathogenesis of Parkinson's
disease (PD), these studies should be carried out on experimental models. We have …

Analysis of monogenic forms and candidate genes of Parkinson's disease (PD) does not
allow to describe completely the contribution of genetic factors to the etiopathogenesis of the …

Degradation of the dopaminergic nigrostriatal system is a central process of the
pathogenesis of Parkinson's disease, which is a chronic neurodegenerative disorder. A …

Parkinson's disease (PD) is a neurodegenerative disorder etiologically linked to the loss of
substantia nigra (SN) dopaminergic neurons in the mid-brain. The etiopathology of sporadic …

A degradation of the nigrostriatal dopaminergic (DA-ergic) system is the key component of
pathogenesis of Parkinson's disease (PD). Initial clinical symptoms appear 20–30 years …

The fight against neurodegenerative diseases, including Parkinson's disease (PD), is
among the global challenges of the 21st century. The low efficiency of therapy is due to the …

Parkinson disease (PD) targets dopaminergic neurons in the substantia nigra, resulting in
motor disturbances such as resting tremor, bradykinesia, and rigidity. Pathogenic processes …

The current treatments of Parkinson disease (PD) are ineffective mainly due to the poor
understanding of the early events causing the decline of dopaminergic neurons (DOPAn) …

Parkinson's disease (PD), dementia with Lewy body (DLB), progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) belong to a …

Studying the initial molecular mechanisms of the pathogenesis of Parkinson's disease (PD),
primarily in the nigrostriatal dopaminergic system, is one of the priorities in neurology. Of …